Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC).

“Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of delivering improved outcomes to patients with significant unmet need,” said Roy Baynes, M.D., Ph.D. Chief Medical Officer of Eikon. “Despite advancements in NSCLC, the current standard of care was established over a decade ago and does not deliver durable benefit for many patients. EIK1001 is designed to drive an enhanced immune response by stimulating both innate and adaptive immunity, improving antigen presentation in secondary lymphoid tissues and recruiting a broader répertoire of T-cells. We are grateful to the patients and investigators participating in this study who are vital partners as we work to develop therapies that may deliver more meaningful and sustained responses for people living with cancer.”